Multisystem Inflammatory Syndrome in Children (MIS-C): Difference between revisions

No edit summary
mNo edit summary
Line 28: Line 28:
* Hypotension  
* Hypotension  


'''Some:'''  
'''<u>Some:</u>'''  


* Abdominal pain  
* Abdominal pain  
Line 106: Line 106:


== Management / Interventions ==
== Management / Interventions ==
The optimal treatment for MIS-C is unknown. 


Several retrospective reviews support the clinical impression that myocardial function normalizes more quickly in children who receive corticosteroid with IVIG<ref name=":3">Belhadjer Z, Auriau J, Méot M, Oualha M, Renolleau S, Houyel L, Bonnet D. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142:2282–4.</ref><ref name=":4">Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–64.</ref> <ref>Son MBF, Murray N, Friedman K, et al (2021) Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med 385:23–34. '''The above 3 studies report more rapid improvement in children with MIS-C treated with corticosteroid therapy.'''</ref>.   
* The optimal treatment for MIS-C is unknown. 
* All children should be treated as suspected COVID-19 
* For mild to moderate disease supportive care only is recommended.<ref name=":2" /> 
* Milder cases of MIS-C may be self-limited and could improve with supportive care alone<ref>Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130:5942–50.</ref>. 
* Several retrospective reviews support the clinical impression that myocardial function normalizes more quickly in children who receive corticosteroid with IVIG<ref name=":3">Belhadjer Z, Auriau J, Méot M, Oualha M, Renolleau S, Houyel L, Bonnet D. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142:2282–4.</ref><ref name=":4">Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–64.</ref> <ref>Son MBF, Murray N, Friedman K, et al (2021) Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med 385:23–34. '''The above 3 studies report more rapid improvement in children with MIS-C treated with corticosteroid therapy.'''</ref>.   
* The optimal dose of corticosteroid for MIS-C remains unknown, but in two studies, doses in the <u>1–2-mg/kg/day</u> range were used; many centers use a tapering dose regimen over a 2–3-week period.<ref name=":3" /><ref name=":4" />
* The role of IVIG in treatment remains unclear.
* Some centers have had success with corticosteroid treatment without IVIG in some patients<ref>Bar-Meir M, Guri A, Godfrey ME, Shack AR, Hashkes PJ, Goldzweig O, Megged O. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep. 2021;11:13840.</ref> <ref>V Vukomanovic S Krasic S Prijic S Ninic S Popovic G Petrovic S Ristic R Simic I CerovicD Nesic 2021 Recent experience: corticosteroids as a first-line therapy in children with multisystem inflammatory syndrome and COVID-19-related myocardial damage Pediatr Infect Dis J https://doi.org/10.1097/INF.0000000000003260</ref>.
* Anakinra or infliximab is the line of treatment in patients who do not appear to respond to IVIG and corticosteroid , but the efficacy and role of these agents are also presently unknown.


The optimal dose of corticosteroid for MIS-C remains unknown, but in two studies, doses in the 1–2-mg/kg/day range were used; many centers use a tapering dose regimen over a 2–3-week period.<ref name=":3" /><ref name=":4" />
== Physiotherapy treatment ==


The role of IVIG in treatment remains unclear.
* Physiotherapy can be initiated to treat  critical illness myopathy<ref>https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1264060</ref>.<br>Children admitted to intensive care units are prone to acquired muscle weakness. 
 
* Play therapy contributes a major  role of physiotherapy to increase the range of motions in the joints, strength, breathing capacity, cardiovascular tolerance during work out resulted in favorable pulmonary function.
Some centers have had success with corticosteroid treatment without IVIG in some patients<ref>Bar-Meir M, Guri A, Godfrey ME, Shack AR, Hashkes PJ, Goldzweig O, Megged O. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep. 2021;11:13840.</ref> <ref>V Vukomanovic S Krasic S Prijic S Ninic S Popovic G Petrovic S Ristic R Simic I CerovicD Nesic 2021 Recent experience: corticosteroids as a first-line therapy in children with multisystem inflammatory syndrome and COVID-19-related myocardial damage Pediatr Infect Dis J https://doi.org/10.1097/INF.0000000000003260</ref>. Patients who do not appear to respond to IVIG and corticosteroid are often treated with anakinra or infliximab, but the efficacy and role of these agents are also presently unknown. It also should be recognized that milder cases of MIS-C may be self-limited and could improve with supportive care alone [21].<br>
* The close contact with the child during actions such as positioning, play therapy, and ambulation pose the risk of spread of the disease<ref>https://www.researchgate.net/profile/Parisa-Arzani/publication/347902548_e24_Epidemiology_and_Prevention_Immunopathol_Persa/links/5fe63a21a6fdccdcb80097a8/e24-Epidemiology-and-Prevention-Immunopathol-Persa.pdf</ref>.  
 
* Hence, all Covid - 19 protocols must be strictly followed by Physiotherapist while treating the child.   
<br>
 
== Differential Diagnosis<br> ==


== Differential Diagnosis ==
This rare syndrome shares common features with other paediatric inflammatory conditions including: Kawasaki disease, staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis and macrophage activation syndromes. It can also present with unusual abdominal symptoms with excessive inflammatory markers.<ref name=":2" /><br>  
This rare syndrome shares common features with other paediatric inflammatory conditions including: Kawasaki disease, staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis and macrophage activation syndromes. It can also present with unusual abdominal symptoms with excessive inflammatory markers.<ref name=":2" /><br>  



Revision as of 18:46, 17 November 2021

Original Editor - User Name
Top Contributors - Rishika Babburu

Introduction[edit | edit source]

A multisystem inflammatory syndrome in children (MIS-C) is associated with coronavirus disease 2019.[1]Since December 2019, the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), has resulted in high morbidity and mortality worldwide. One of the most intriguing and mysterious phenomena observed during the COVID-19 pandemic has been represented by the occurrence of the multisystem inflammatory syndrome in children and adolescents (MIS-C).[2] Multisystem inflammatory disorder in children (MIS-C) most commonly affects young, school-aged children and is characterized by persistent fever, systemic hyperinflammation, and multisystem organ dysfunction.[3] In early May, the United Kingdom and several European countries reported the occurrence of a hyperinflammatory process in children that had features similar to atypical Kawasaki’s disease, Kawasaki’s disease shock syndrome, and toxic shock syndrome, possibly related to SARS-CoV-2 infection.[4][5][6]Patients with this condition have some overlapping signs and symptoms with those of Kawasaki disease (KD), but also display clinical features that are uncommon or less frequent in this illness, such as diarrhea, abdominal pain and myocardial involvement. The sickest patients may develop multiorgan failure and shock, usually due to myocarditis.[2]


Pathological Process[edit | edit source]

The pathophysiology of MIS-C is not well understood.

Immune dysregulation – It has been suggested that the syndrome results from an abnormal immune response to the virus, with some clinical similarities to Kawasaki disease (KD), macrophage activation syndrome (MAS), and cytokine release syndrome. However, based on the available studies, MIS-C appears to have an immunophenotype that is distinct from KD and MAS. The exact mechanisms by which SARS-CoV-2 triggers the abnormal immune response are unknown.Preliminary studies suggest that patients with severe MIS-C have persistent immunoglobulin G (IgG) antibodies with enhanced ability to activate monocytes, persistent cytopenias (particularly T cell lymphopenia), and greater activation of CD8+ T cells that differ from findings in acute COVID-19 infection.[7]

SARS-CoV-2 virus – Many affected children have negative polymerase chain reaction (PCR) testing for SARS-CoV-2 but have positive serology, a finding that further supports the hypothesis that MIS-C is related to immune dysregulation occurring after acute infection has passed. However, some children do have positive PCR testing.[7]

Mechanisms of myocardial injury – The mechanisms of myocardial injury in MIS-C are not well characterized. Possible causes include injury from systemic inflammation, acute viral myocarditis, hypoxia, stress cardiomyopathy, and, rarely, ischemia caused by coronary artery (CA) involvement. Cardiac dysfunction may result from a combination of these mechanisms in some patients.[7]

Clinical Presentation[edit | edit source]

All:

  • Persistent fever >38.5°C

Most:

  • Oxygen requirement
  • Hypotension

Some:

  • Abdominal pain
  • Confusion
  • Conjunctivitis
  • Cough
  • Diarrhoea
  • Headache
  • Lymphadenopathy
  • Mucus membrane changes
  • Neck swelling
  • Rash
  • Respiratory symptoms
  • Sore throat
  • Swollen hands and feet
  • Syncope
  • Vomiting

Investigations[edit | edit source]

  • Full Blood Count
  • Urea and electrolytes
  • Liver function test
  • Glucose
  • Blood gas with lactate
  • Coagulation + fibrinogen
  • D-Dimer
  • Lactate Dehydrogenase(LDH)
  • Triglycerides
  • Ferritin
  • Troponin
  • Pro-BNP
  • Creatine Kinase(CK)
  • Vitamin D
  • Amylase
  • Urinalysis
  • Save EDTA and serum for PCR and serological studies (ideally pre IVIG)
  • Blood culture
  • Urine and Stool culture
  • Throat swab culture
  • NPA or throat swab for respiratory panel plus SARS-CoV-2 PCR
  • Stool and blood for SARS-CoV-2 PCR
  • Pneumococcal, Meningococcal, Group A strep, Staph aureus Blood PCR
  • Antistreptolysin O titer (ASOT)
  • SARS-CoV-2 serology
  • EBV, CMV, Adenovirus, Enterovirus PCR on blood
  • Stool for virology

Laboratory Findings[edit | edit source]

  • Abnormal Fibrinogen
  • Absence of potential causative organisms (other than SARS-CoV-2)
  • High CRP
  • High D-Dimers
  • High ferritin
  • Hypoalbuminaemia
  • Lymphopenia
  • Neutrophilia in most – normal neutrophils in some
  • Acute kidney injury
  • Anaemia
  • Coagulopathy
  • Neutrophilia
  • Proteinuria
  • Raised CK
  • Raised LDH
  • Raised triglycerides
  • Raised troponin
  • Thrombocytopenia
  • Transaminitis

Imaging and ECG[edit | edit source]

  1. Echo and ECG – myocarditis, valvulitis, pericardial effusion, coronary artery dilatation
  2. Chest X Ray – patchy symmetrical infiltrates, pleural effusion
  3. Abdominal ultrasound – colitis, ileitis, lymphadenopathy, ascites, hepatosplenomegaly
  4. CT chest – as for chest x ray – may demonstrate coronary artery abnormalities if with contrast[8]

Management / Interventions[edit | edit source]

  • The optimal treatment for MIS-C is unknown.
  • All children should be treated as suspected COVID-19
  • For mild to moderate disease supportive care only is recommended.[8]
  • Milder cases of MIS-C may be self-limited and could improve with supportive care alone[9].
  • Several retrospective reviews support the clinical impression that myocardial function normalizes more quickly in children who receive corticosteroid with IVIG[10][11] [12].
  • The optimal dose of corticosteroid for MIS-C remains unknown, but in two studies, doses in the 1–2-mg/kg/day range were used; many centers use a tapering dose regimen over a 2–3-week period.[10][11]
  • The role of IVIG in treatment remains unclear.
  • Some centers have had success with corticosteroid treatment without IVIG in some patients[13] [14].
  • Anakinra or infliximab is the line of treatment in patients who do not appear to respond to IVIG and corticosteroid , but the efficacy and role of these agents are also presently unknown.

Physiotherapy treatment[edit | edit source]

  • Physiotherapy can be initiated to treat critical illness myopathy[15].
    Children admitted to intensive care units are prone to acquired muscle weakness.
  • Play therapy contributes a major role of physiotherapy to increase the range of motions in the joints, strength, breathing capacity, cardiovascular tolerance during work out resulted in favorable pulmonary function.
  • The close contact with the child during actions such as positioning, play therapy, and ambulation pose the risk of spread of the disease[16].
  • Hence, all Covid - 19 protocols must be strictly followed by Physiotherapist while treating the child.

Differential Diagnosis[edit | edit source]

This rare syndrome shares common features with other paediatric inflammatory conditions including: Kawasaki disease, staphylococcal and streptococcal toxic shock syndromes, bacterial sepsis and macrophage activation syndromes. It can also present with unusual abdominal symptoms with excessive inflammatory markers.[8]

Resources
[edit | edit source]

add appropriate resources here

References[edit | edit source]

  1. https://www.nejm.org/doi/full/10.1056/NEJMoa2021756#article_references
  2. 2.0 2.1 https://www.frontiersin.org/articles/10.3389/fped.2021.680813/full#B1
  3. https://www.sciencedirect.com/science/article/pii/S1876034121000125
  4. Jones VG, Mills M, Suarez D, et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 2020;10:537-540.
  5. European Centre for Disease Prevention and Control. Rapid risk assessment: paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. May 15, 2020
  6. Verdoni L, Mazza A, Gervasoni A, et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 2020;395:1771-1778.
  7. 7.0 7.1 7.2 https://www.uptodate.com/contents/covid-19-multisystem-inflammatory-syndrome-in-children-mis-c-clinical-features-evaluation-and-diagnosis
  8. 8.0 8.1 8.2 https://www.rcpch.ac.uk/sites/default/files/2020-05/COVID-19-Paediatric-multisystem-%20inflammatory%20syndrome-20200501.pdf
  9. Lee PY, Day-Lewis M, Henderson LA, et al. Distinct clinical and immunological features of SARS–CoV-2–induced multisystem inflammatory syndrome in children. J Clin Invest. 2020;130:5942–50.
  10. 10.0 10.1 Belhadjer Z, Auriau J, Méot M, Oualha M, Renolleau S, Houyel L, Bonnet D. Addition of corticosteroids to immunoglobulins is associated with recovery of cardiac function in multi-inflammatory syndrome in children. Circulation. 2020;142:2282–4.
  11. 11.0 11.1 Ouldali N, Toubiana J, Antona D, et al. Association of intravenous immunoglobulins plus methylprednisolone vs immunoglobulins alone with course of fever in multisystem inflammatory syndrome in children. JAMA. 2021;325:855–64.
  12. Son MBF, Murray N, Friedman K, et al (2021) Multisystem inflammatory syndrome in children - initial therapy and outcomes. N Engl J Med 385:23–34. The above 3 studies report more rapid improvement in children with MIS-C treated with corticosteroid therapy.
  13. Bar-Meir M, Guri A, Godfrey ME, Shack AR, Hashkes PJ, Goldzweig O, Megged O. Characterizing the differences between multisystem inflammatory syndrome in children and Kawasaki disease. Sci Rep. 2021;11:13840.
  14. V Vukomanovic S Krasic S Prijic S Ninic S Popovic G Petrovic S Ristic R Simic I CerovicD Nesic 2021 Recent experience: corticosteroids as a first-line therapy in children with multisystem inflammatory syndrome and COVID-19-related myocardial damage Pediatr Infect Dis J https://doi.org/10.1097/INF.0000000000003260
  15. https://pesquisa.bvsalud.org/global-literature-on-novel-coronavirus-2019-ncov/resource/pt/covidwho-1264060
  16. https://www.researchgate.net/profile/Parisa-Arzani/publication/347902548_e24_Epidemiology_and_Prevention_Immunopathol_Persa/links/5fe63a21a6fdccdcb80097a8/e24-Epidemiology-and-Prevention-Immunopathol-Persa.pdf